AstraZeneca's breast cancer drug fails in late-stage trial
AstraZeneca's LSE:AZN breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved treatment.U.S.-listed shares of AstraZeneca fell 3% in aftermarket trading.The drug, branded as Etca…